Skip to content
Clinical Trials – home

Dr. Ivo Natsov Outpatient Clinic For Individual Practice For Specialized Medical Care In Psychiatry ET

Research site

Bulgaria Ulitsa Yane Sandanski 61, 5980 Cherven Bryag, Bulgaria

  • 7 trials recruiting
  • Major depression · Dementia Alzheimer's type · Dementia with Lewy bodies
  • Adult patients

About Specializations

Dr. Ivo Natsov Outpatient Clinic For Individual Practice For Specialized Medical Care In Psychiatry ET in Cherven Bryag, Bulgaria specialises in clinical trials of conditions such as Major depression, Dementia Alzheimer's type, Dementia with Lewy bodies, Schizophrenia, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Mental Disorders

At Dr. Ivo Natsov Outpatient Clinic For Individual Practice For Specialized Medical Care In Psychiatry ET, clinical research focuses on major depressive disorder and related mood symptoms. The studies are designed to test new treatment options, compare them with placebo, and better understand how well they may help people whose depression is not fully controlled.

  • Research in major depressive disorder and treatment-resistant depression
  • Evaluation of new therapies aimed at improving depressive symptoms
  • Long-term assessment of safety, tolerability, and treatment benefit

This work supports the search for more effective and better-tolerated approaches for people living with persistent depression.

Nervous System Diseases and Behavior and Behavior Mechanisms

The site also contributes to research on schizophrenia, with studies aimed at easing inadequately controlled symptoms and understanding overall treatment effectiveness. These trials are focused on evaluating new adjunctive therapies and monitoring their longer-term safety in everyday clinical use.

  • Studies in schizophrenia and symptom control
  • Testing add-on treatment strategies for better symptom management
  • Ongoing evaluation of safety and tolerability over time

This area reflects a strong interest in improving outcomes for people with chronic psychotic disorders.

Psychosis in Alzheimer Disease and Lewy Body Dementia

Research at this Bulgarian clinic includes studies of psychosis linked to Alzheimer’s disease and Lewy body dementia. The main goal is to assess whether new therapies can reduce hallucinations, delusions, and other behavioral symptoms while remaining safe and well tolerated.

  • Trials in psychosis associated with Alzheimer’s disease
  • Studies in Lewy body dementia psychosis
  • Testing treatments intended to improve behavioral and psychotic symptoms

These studies help address some of the most challenging neuropsychiatric complications seen in dementia care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ulitsa Yane Sandanski 615980 Cherven BryagBulgaria
Recruiting now
7 trials
Conditions studied
7

More sites in Cherven BryagBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

14 clinical trials

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Neurocrine Biosciences Inc.

A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Draig Therapeutics Limited

A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Psychotic disorder+2

Recruiting

Study on ITI-1284 for Treating Psychosis in Alzheimer's Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ITI-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Study on Lumateperone for Patients with Major Depressive Disorder Not Responding to Antidepressants

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lumateperone
  • Sponsor:Intra-Cellular Therapies Inc.

Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Schizophrenia

Not recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) in patients with inadequately controlled schizophrenia symptoms

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Karuna Therapeutics Inc.

Major depression

Not recruiting

Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Study of ACP-204 for Treating Psychosis in Adults with Alzheimer's Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Schizophrenia

Not recruiting

Study of KarXT (trospium chloride and xanomeline tartrate) in patients with inadequately controlled schizophrenia symptoms

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Karuna Therapeutics Inc.
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.